Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Update

Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 154,100 shares, a growth of 34.1% from the January 31st total of 114,900 shares. Currently, 1.1% of the company's stock are sold short. Based on an average daily trading volume, of 226,700 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Northern Trust Corp increased its position in shares of Ikena Oncology by 19.7% during the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company's stock worth $94,000 after purchasing an additional 9,456 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Ikena Oncology by 5.6% during the third quarter. Geode Capital Management LLC now owns 271,026 shares of the company's stock valued at $469,000 after acquiring an additional 14,319 shares in the last quarter. FMR LLC raised its position in shares of Ikena Oncology by 94.1% in the 3rd quarter. FMR LLC now owns 38,374 shares of the company's stock valued at $66,000 after purchasing an additional 18,607 shares during the last quarter. NEA Management Company LLC raised its position in shares of Ikena Oncology by 5.3% in the 3rd quarter. NEA Management Company LLC now owns 600,063 shares of the company's stock valued at $1,038,000 after purchasing an additional 30,013 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Ikena Oncology in the 4th quarter worth approximately $72,000. Hedge funds and other institutional investors own 75.00% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wedbush restated a "neutral" rating and issued a $2.00 price objective on shares of Ikena Oncology in a report on Monday, December 23rd. HC Wainwright restated a "buy" rating and issued a $4.00 price target on shares of Ikena Oncology in a report on Monday, November 11th.

Ikena Oncology Price Performance

NASDAQ IKNA traded up $0.01 during midday trading on Friday, hitting $1.44. 72,039 shares of the company traded hands, compared to its average volume of 199,749. Ikena Oncology has a 52 week low of $1.22 and a 52 week high of $1.94. The company's 50-day simple moving average is $1.49 and its 200-day simple moving average is $1.62. The company has a market cap of $69.49 million, a PE ratio of -1.17 and a beta of 0.49.

Ikena Oncology (NASDAQ:IKNA - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. On average, research analysts predict that Ikena Oncology will post -0.91 earnings per share for the current year.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.